| Literature DB >> 23671631 |
Mads U Werner1, Karin L Petersen, Michael C Rowbotham, Jørgen B Dahl.
Abstract
BACKGROUND: Human experimental pain models leading to development of secondary hyperalgesia are used to estimate efficacy of analgesics and antihyperalgesics. The ability to develop an area of secondary hyperalgesia varies substantially between subjects, but little is known about the agreement following repeated measurements. The aim of this study was to determine if the areas of secondary hyperalgesia were consistently robust to be useful for phenotyping subjects, based on their pattern of sensitization by the heat pain models.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23671631 PMCID: PMC3650051 DOI: 10.1371/journal.pone.0062733
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Published (2,4–8,11–13) and unpublished volunteer studies on induced secondary hyperalgesia areas.
| Author | Ref. | Year | N (female/male) | Age (yrs) | Study aim | Study design | Study model | Number of sessions |
|
|
| 2000 | 24 (0/24) | n.a. (21–30) | effect on pain and secondary hyperalgesia by i.v. lidocaine. | DB, R, X, dose-response | Heat/Capsaicin | 2 |
|
|
| 2001 | 14 (5/9) | 34 (22–56) | effect on pain and secondary hyperalgesia by i.v. remifentanil. | DB, PC, R, X | Heat/Capsaicin | 2 |
|
|
| 2001 | 25 (0/25) | n.a. (20–30) | effect on pain and secondary hyperalgesia by i.v. adenosine | DB, PC, R, X | Heat/Capsaicin | 2 |
|
|
| 2001 | 25 (0/25) | 26 (21–42) | effect on pain and secondary hyperalgesia by i.v. magnesium | DB, PC, R, X | Heat/Capsaicin | 2 |
|
|
| 2002 | 25 (0/25) | n.a. (20–30) | effect on pain and secondary hyperalgesia by gabapentin | DB, PC, R, X | BTS; Heat/Capsaicin | 2 |
|
|
| 2003 | 20 (0/20) | 25 (18–44) | methodology: synergy between capsaicin and heat | descriptive | BTS; Heat/Capsaicin | 2 |
|
|
| 2007 | 22 (14/8) | 27 (22–39) | effect on pain and secondary hyperalgesia by morphine, dextrometorphan | DB, PC, R, X | BTS; Heat/Capsaicin | 4 |
|
|
| 2008 | 53 (23/30) | 28 (21–51) | analgesic tolerance to morphine | DB, PC, P, R | BTS | 4 |
|
|
| 2012 | 100 (50/50) | 24 (20–37) | experimental pain sensitivity | descriptive | Burn Injury | 2 |
|
| - | Unpublished | 34 (18/16) | 28 (18–54) | effect on pain and secondary hyperalgesia by tramadol, topiramate and gabapentin | PC, CB, DB, X | Heat/Capsaicin | 4 |
BTS = brief thermal sensitization, CB = complete block design, DB = double-blind, PC = placebo-controlled, P = parallel, R = randomized, X = cross-over.
data from intention-to-treat population,
4-period, 4-treatment, and 4-sequence study.
Figure 1Basic scatterplots of area of secondary hyperalgesia (cm2), first vs. second measurement, in the heat/capsacin model (panel A, pooled data from eight studies [n = 189]), the brief thermal stimulation model (panel B, pooled data from four studies [n = 120]) and the burn injury model (panel C, data from one study [n = 100]).
The Spearman’s rank correlation coefficient (rho) and line of identity are indicated.
Areas of secondary hyperalgesia for measurement 1 and 2 (mean +/− SD), P-values for paired t-tests between measurements, Spearman’s rank correlation coefficient (rho), coefficient of variation (CV, mean +/− SD), intra-class correlation coefficient (ICC, 95% CI) for 2 measurements and for data with more than 2 measurements.
| Measures of Area of Secondary Hyperalgesia (cm2) | 2 measurements | >2 measurements | |||||||||
| Measurement 1 | Measurement 2 | ▵Measurement | CV | ICC | ICC | ||||||
| Study | N | mean +/− SD | mean +/− SD | mean +/− SD |
| Rho | mean +/− SD | (95% CI) | (95% CI) | ||
|
| |||||||||||
|
| 24 | 99.82+/−41.81 | 103.20+/−39.49 | −3.38+/−40.55 | 0.69 | 0.50 | 20.48+/−12.95 | 0.52 (0.16, 0.76) | – | ||
|
| 14 | 141.48+/−76.77 | 143.28+/−60.64 | −1.80+/−49.91 | 0.89 | 0.76 | 16.94+/−14.90 | 0.76 (0.41, 0.91) | – | ||
|
| 25 | 96.04+/−36.81 | 95.50+/−39.40 | 0.53+/−29.70 | 0.93 | 0.70 | 19.75+/−18.32 | 0.71 (0.44, 0.86) | – | ||
|
| 25 | 83.16+/−29.85 | 87.61+/−27.63 | −4.45+/−27.50 | 0.43 | 0.54 | 19.30+/−12.68 | 0.55 (0.21, 0.77) | – | ||
|
| 25 | 118.67+/−61.48 | 134.62+/−46.54 | −15.95+/−40.20 | 0.06 | 0.76 | 18.03+/−21.09 | 0.70 (0.43, 0.86) | – | ||
|
| 20 | 94.70+/−45.04 | 97.75+/−43.96 | −3.05+/−53.44 | 0.80 | 0.28 | 26.12+/−22.99 | 0.30 (−0.14, 0.65) | 0.66 (0.49, 0.82) | ||
|
| 21 | 86.52+/−41.79 | 79.02+/−46.77 | 7.50+/−34.09 | 0.33 | 0.71 | 25.79+/−23.22 | 0.70 (0.41, 0.87) | 0.69 (0.48, 0.84) | ||
|
| 34 | 140.75+/−73.54 | 133.50+/−64.95 | 7.26+/−57.06 | 0.46 | 0.67 | 19.23+/−15.75 | 0.67 (0.43, 0.82) | 0.68 (0.51, 0.81) | ||
|
| 188 | 108.08+/−56.75 | 109.47+/−51.83 | −1.38+/−42.84 | 0.66 | 0.69 | 20.60+/−17.91 | 0.69 (0.61, 0.76) | – | ||
|
| |||||||||||
|
| 25 | 198.93+/−108.54 | 220.64+/−100.88 | −21.71+/−55.67 | 0.06 | 0.86 | 14.24+/−18.30 | 0.84 (0.68, 0.93) | – | ||
|
| 20 | 201.65+/−125.22 | 170.20+/−73.41 | 31.45+/−102.85 | 0.19 | 0.57 | 29.90+/−19.50 | 0.48 (0.07, 0.76) | 0.81 (0.70, 0.90) | ||
|
| 22 | 150.06+/−79.17 | 128.94+/−83.59 | 21.12+/−64.01 | 0.14 | 0.69 | 25.87+/−21.34 | 0.67 (0.37, 0.85) | 0.76 (0.59, 0.88) | ||
|
| 53 | 130.37+/−58.70 | 142.56+/−63.56 | −12.19+/−37.46 | 0.02 | 0.82 | 16.04+/−12.57 | 0.80 (0.67, 0.88) | 0.83 (0.74, 0.89) | ||
|
| 120 | 160.14+/−92.25 | 160.94+/−83.75 | −0.79+/−63.75 | 0.89 | 0.74 | 19.78+/−17.73 | 0.74 (0.65, 0.81) | – | ||
|
| |||||||||||
|
| 100 | 45.03+/−29.39 | 37.22+/−25.00 | 7.81+/−24.21 | 0.002 | 0.64 | 28.60+/−21.36 | 0.58 (0.43, 0.69) | 0.71 (0.64, 0.77) | ||
Measure 1 is from Day 1 (or placebo day if no day order was specified) and Measure 2 is the first measurement from the next day where measures were repeated. Measure 1 is the first measurement from Day 1 (or placebo day if no day order was specified) and Measure 2 is the first measurement from the next day where measures were repeated.
= unpublished study.
Measure 1 is from the placebo day, measure 2 is from treatment day. Day order was randomized, so measurement 1 may not have come before measurement 2.
Figure 2Bland-Altman plots illustrating the mean of measurement 1 and measurement 2 (x-axis) plotted against the difference between measurement 1 and measurement 2 (y-axis) for secondary hyperalgesia areas induced by the heat/capsacin model (panel A, pooled data from eight studies [n = 189]), the brief thermal stimulation model (panel B, pooled data from four studies [n = 120]) and the burn injury model (panel C, data from one study [n = 100]).
The solid vertical line (mean of difference) indicate bias between the methods and the dashed vertical lines indicate the upper and lower 95% confidence interval (CI [±1.96×SD = limits of agreement]).
Agreement of secondary hyperalgesia areas in the heat/capsaicin (left part of table), brief thermal sensitization (BTS [middle part of table]) and the burn injury (right part of model) model, at Measurement 1 (rows) and Measurement 2 (columns).
| Heat/capsaicin | Brief Thermal Sensitization | Burn injury | ||||||||||||||
| Measurement 2 | Measurement 2 | Measurement 2 | ||||||||||||||
| <25% | 25–50% | 51–75% | >75% | Sum | <25% | 25–50% | 51–75% | >75% | Sum | <25% | 25–50% | 51–75% | >75% | Sum | ||
|
|
| 31 | 12 | 4 | 1 |
| 21 | 7 | 2 | 0 |
| 16 | 9 | 0 | 0 |
|
|
| 11 | 16 | 16 | 5 |
| 7 | 10 | 11 | 2 |
| 7 | 10 | 5 | 3 |
| |
|
| 5 | 14 | 18 | 9 |
| 2 | 11 | 12 | 5 |
| 2 | 6 | 9 | 8 |
| |
|
| 0 | 6 | 10 | 31 |
| 0 | 2 | 6 | 22 |
| 0 | 0 | 11 | 14 |
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||
Data indicate the distribution of observations split into quartiles (<25%, 25–50%, 51–75%, >75%) giving a 4×4 contingency table (total number of observations for each quartile are indicated in lower row [Measurement 2] and right-hand column [Measurement 1]). The numbers in the lower right-hand corner, in each panel, are the total number of observations. The numbers in bold indicate completely agreement between observations: Measurement 1 and Measurement 2. Perfect agreement for the heat/capsaicin (A), brief thermal stimulation (B) and the burn injury (C) models were seen in 51%, 54% and 49% of the observations, respectively. The weighted Cohen’s kappa statistics were 0.66 (95% CI: 0.57–0.74) for the heat/capsaicin model, 0.74 (0.65–0.82) for the brief thermal stimulation and 0.74 (0.65–0.82) for the burn injury model.
The table illustrates the probability of measurement 2 moving more than one quartile away from measurement 1 and vice versa for the heat/capsaicin, brief thermal sensitization (BTS) and burn injury models.
| Heat/capsaicin | BTS | Burn injury | |||||
| ≥50% | <50% | ≥50% | <50% | ≥50% | <50% | ||
|
|
| 5/48 |
| 2/30 |
| 0/25 |
|
|
| 5/47 |
| 2/30 |
| 2/25 |
| |
|
|
|
| 6/47 |
| 2/30 |
| 0/25 |
|
|
| 6/46 |
| 2/29 |
| 3/25 | |
The distribution of the lowest (<25%) and highest (>75%) quartiles (rows [split into Measurement 1 and Measurement 2 observations]) divided in the 2 higher (≥50%) and the 2 lower (<50%) quartiles (columns), across the 3 different models. As an example: in the heat/capsaicin model the number of observations Measurement 1 with areas in the highest quartile (>75% [n = 47]) corresponded at Measurement 2 to 41 observations at or above the median (≥50%) and 6 observations below median value (<50%).
Comparing the area categorizations (small, mid, large) between the heat/capsaicin and the brief thermal sensitization methods when measured on the same subject at the same time.
| Pooled | ||||||
|
| ||||||
| Measurement 1 | Measurement 2 | |||||
|
| Small-area | Mid-area | Large-area | Small-area | Mid-area | Large-area |
|
| 8 (12.1%) | 8 (12.1%) | 3 (4.6%) | 17 (25.4%) | 7 (10.4%) | 0 |
|
| 5 (7.6%) | 18 (27.3%) | 9 (13.6%) | 0 | 18 (26.9%) | 10(14.9%) |
|
| 0 | 2 (3.0%) | 13 (19.7%) | 0 | 4 (6.0%) | 11 (16.4%) |
| Perfect agreement: | 39 (59.0%) | 46 (68.7%) | ||||
| Agreement moving >1 level: | 3 (4.6%) | 0 (0%) | ||||
The agreement in classification to small-, mid- or large areas across induction methods was 59% for measurement 1 and 69% for measurement 2.
The weighted Cohen’s kappa statistic for the pooled analyses showed moderate agreement for measurement 1 (0.44) and substantial agreement for measurement 2 (0.62).
| Measurement 1 | Measurement 2 | ||||
| Weighted | Weighted | ||||
|
|
|
|
|
|
|
|
| 25 | 0.48(0.23,0.74) | 0.01 | 0.67 (0.41,0.93) | <0.0001 |
|
| 20 | 0.49 (0.21,0.77) | 0.002 | 0.34 (0.03,0.65) | 0.03 |
|
| 22 | 0.24 (−0.09,0.58) | 0.1 | 0.57 (0.32,0.84) | 0.0003 |
|
|
|
|
|
|
|
The kappa statistics were significantly different from zero (what would be expected from chance alone) for 1 comparison.